Immunome, Inc. (IMNM)
Last updated: 2026-10-24 09:39:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Immunome, Inc. (IMNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.00, with a market capitalization of $2.15B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.64 to $30.06. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$2.15B | |
$18.13 | |
$63.78 | |
$2.09 | |
$18.26 | |
1.11M | |
1.28M | |
-- | |
$30.06 | |
$14.64 | |
-- | |
-- |
Immunome, Inc. (IMNM) Latest Closing Stock Price
Immunome, Inc. (IMNM) last closed at $18.26 as of 2026-10-23 23:31:00, unchanged from the previous close of $18.26.
During the latest regular trading session, IMNM traded between $2.09 and $63.78, with a volume of 1.11M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Immunome, Inc. (IMNM) 7-Day Stock Price Change
Over the past seven days, Immunome, Inc. (IMNM) moved from $17.40 to $18.00, representing a gain of 3.42% ($0.60).
The stock traded between $16.41 and $19.23 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.54 million shares, down versus the previous seven-day period, indicating lower trading activity.
IMNM 52-Week Price Position
Position in Range: 21.8%
IMNM is currently trading at $18.00, placing it 21.8% of the way from its 52-week low of $14.64 to its 52-week high of $30.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Immunome, Inc. (IMNM)?
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Immunome, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 177 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Immunome, Inc. (IMNM) Stock on MEXC
Eligible investors can buy real shares of Immunome, Inc. (IMNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Immunome, Inc. (IMNM) stock price today?
2.Is IMNM stock going up or down today?
3.What is IMNM pre-market price?
4.What is IMNM after-hours price?
5.Is IMNM stock trading now?
6.Where does IMNM sit relative to its 52-week high and low?
7.What sector is Immunome, Inc. in?
8.What is Immunome, Inc.'s market capitalization and where is it listed?
9.How is IMNM valued in terms of P/E ratio and EPS?
10.Does Immunome, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
IMNM Stock Calculator
Estimate the value between IMNM shares and USD.
IMNM Shares to USD
1.00 IMNM shares = 17.995 USD
Calculations are estimates based on the latest available price and are for reference only.


